|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 701 PENNSYLVANIA AVENUE, NW, #725 |
Address2 | |
| City | WASHINGTON |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
| City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 9204-12
|
||||||||
|
6. House ID# 335890000
|
||||||||
| TYPE OF REPORT | 8. Year | 2008 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: James Elkin, Vice President, Federal Government Relations |
Date | 04/21/2008 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
HR4703, S2467, HR4991 - Vaccine Shortage Preparedness Act of 2008
S2464, HR4992, HR4704 - A bill to amend title XVIII of the Social Security Act to provide for coverage of federally recommended vaccines under Medicare part B
S. 2465, HR 4702, HR 4990 A bill to amend title XIX of the Social Security Act to include all public clinics for the distribution of pediatric vaccines under the Medicaid program.
S. 2467, HR 4703, HR 4991 A bill to amend the Social Security Act, the Federal Food, Drug and Cosmetic Act, and the Public Health Service Act to ensure a sufficient supply of vaccines, and for other purposes.
HR4705 - Vaccines for the Uninsured Adult Act of 2008
S3678
H.R. 970 and S. 1378 - Dextromethorphan Distribution Act of 2007
S.3678 Pandemic All Hazards Preparedness Act (Biodefense)
S.103 Combat Meth Act of 2005
H.R. 2207 - Agricultural Disaster Assistance and Western States Emergency Unfinished Business Appropriations Act of 2007
H.R. 1908 and S. 1710 - Patent Reform Act of 2007
H.R 1 - Implementing the 9/11 Commission Recommendations Act of 2007
H.R. 3162 - Children's Health and Medicare Protection Act of 2007
S. 1505 Affordable Biologics for Consumers Act
S. 1695 Biologics Price Competition and Innovation Act of 2007
H.R. 1956 Patient Protection and Innovative Biologic Medicines Act of 2007
H.R. 1038 Access to Life-Saving Medicine Act
S.623 Access to Life-Saving Medicine Act
H.R. 4083 Non-Prescription Drug Modernization Act of 2007
S. 2311 Non-Prescription Drug Modernization Act of 2007
Comparative Effectiveness Research
Public Health Service Act
Drug Importation
Gene Therapy
Direct to Consumer Advertising
Drug Safety Legislation
Global Hypertension
Best Pharmaceuticals for Children's Act
Pediatric Research Equity Act
Pharmaceuticals in water
FDA Funding
Reagan/Udall Foundation
Counter Detailing
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
James |
Elkin |
|
|
|
Daniel |
Casserly |
|
|
|
Thomas |
Giles |
|
|
|
David |
Drake |
|
|
|
Katherine |
Solon |
|
|
|
Sarah |
Haller |
|
|
|
Gene |
Hughes |
|
|
|
Marguerite |
Baxter |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Free Trade Agreements:
- Intellectual Property Provisions in Peru, Columbia, Korea
17. House(s) of Congress and Federal agencies Check if None
Commerce - Dept of (DOC), U.S. Agency for International Development (USAID), U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Sarah |
Haller |
|
|
|
Renard |
Aron |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
DoD Authorization language - Section 701, Dealing with TriCare
H.R. 3282 - Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007
FY 2009 Labor HHS Appropriations Bill - Pandemic Influenza Funding and Weldon Ammendment on Thimerosal and Vaccines
2009 Supplemental Appropriations Bill
FY 2009 Department of Defense Appropriations Bill
- Transformational Medical Technologies Initiative
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
James |
Elkin |
|
|
|
Daniel |
Casserly |
|
|
|
Thomas |
Giles |
|
|
|
David |
Drake |
|
|
|
Katherine |
Solon |
|
|
|
Sarah |
Haller |
|
|
|
Gene |
Hughes |
|
|
|
Marguerite |
Baxter |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
S. 2029 Physician Payments Sunshine Act of 2007
H.R. 6111 Tax Relief and health Care Act (Medicare)
Access to Life Saving Medicines Act
Medicare Part B and Part D - Part D: Non-Interference Part B: Prompt Pay Removal from Average Sales Price Calculation
Immunosuppressant Legislation
Medicare Prescription Drugs and Modernization Act
H.R.2184 Enhanced Health Care Value for All Act of 2007
H.R.3023 Drug and Medical Device Company Gift Disclosure Act
H.R. 3963Children's Health Insurance Program Reauthorization Act of 2007
S.2041 False Claims Act Correction Act of 2007
HR 4854 False Claims Act Correction Act of 2007
HR3610 Food and Drug Import Safety Act of 2007
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
James |
Elkin |
|
|
|
Daniel |
Casserly |
|
|
|
Thomas |
Giles |
|
|
|
David |
Drake |
|
|
|
Katherine |
Solon |
|
|
|
Sarah |
Haller |
|
|
|
Gene |
Hughes |
|
|
|
Marguerite |
Baxter |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
S.1145 Patent Reform Act of 2007
H.R.1908 Patent Reform Act of 2007
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
James |
Elkin |
|
|
|
Daniel |
Casserly |
|
|
|
Thomas |
Giles |
|
|
|
David |
Drake |
|
|
|
Katherine |
Solon |
|
|
|
Sarah |
Haller |
|
|
|
Gene |
Hughes |
|
|
|
Marguerite |
Baxter |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address | |
||||||
| City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
| City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
7 |
|
||||||
| 2 |
|
8 |
|
||||||
| 3 |
|
9 |
|
||||||
| 4 |
|
10 |
|
||||||
| 5 |
|
11 |
|
||||||
| 6 |
|
12 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 4 | 7 |
| 2 | 5 | 8 |
| 3 | 6 | 9 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 7 | 13 |
| 2 | 8 | 14 |
| 3 | 9 | 15 |
| 4 | 10 | 16 |
| 5 | 11 | 17 |
| 6 | 12 | 18 |